A groundbreaking shift in Canadian drug policy has occurred, as the regulators permit the availability of psilocybin hallucinogens for therapeutic treatment. Previously, these substances were severely restricted, but a growing body of research suggests they potentially offer relief for psychological conditions like PTSD. This development represents